XTalks

OCTOBER 4, 2023

Health economics and outcomes research (HEOR) and market access strategies play a critical role in ensuring that newly approved therapies are made available to patients. Professionals in these roles are facing new challenges when it comes to negotiating coverage for many of the new, innovative treatments that are coming to market.

Marketing 105

Marketing Development Drugs Gene Therapy 105

Pharmaceutical Technology

DECEMBER 15, 2022

Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments. Under the deal, the parties intend to develop treatments for diseases including Alzheimer’s and Parkinson’s.

Development 246

Development Medicine Sales Scientist 246

Pharmaceutical Technology

MAY 8, 2023

Shanghai Junshi Biosciences and Dr. Reddy’s Laboratories have partnered for the development and commercialisation of the anti-PD-1 monoclonal antibody, toripalimab, in 21 countries.

Development 130

Development Marketing Licensing Licensing 130

Outsourcing Pharma

MAY 29, 2024

UK based Celadon Pharmaceuticals Plc, that specializes in the development, production, and sale of breakthrough cannabis-based medicines, announced that it has begun shipping to the US.

Medicine 79

Medicine Sales Production Development 79

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The partnership will focus on developing potential new vaccines to treat certain selected autoimmune indications, as well as food allergies.

Vaccination 245

Vaccination Vaccine Development Allergies 245

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 92

Genome Genomics Medicine Development 92

Pharmaceutical Technology

DECEMBER 20, 2022

The European Commission (EC) has granted marketing authorization for Atara Biotherapeutics’ Ebvallo (tabelecleucel) as a monotherapy to treat Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) patients. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Marketing 298

Marketing Gene Therapy Gene Medicine 298

Pharmaceutical Technology

DECEMBER 15, 2022

France’s temporary authorisation system (autorisation temporaire d’utilisation, ATU) was developed to provide early market access for treatments in therapeutic areas with unmet medical need, limited therapeutic alternatives, or where no authorised alternatives are available.

Medicine 147

Medicine Marketing Drugs Branding 147

Pharmaceutical Technology

APRIL 27, 2023

The European Commission’s (EC) long-anticipated pharma reform plans in the European Union have finally been unveiled , indicating a focus on improving access to medicines across the bloc while cutting down on market exclusivity. However, the reform has its share of critics. Applications will now be digitised.

Marketing 264

Marketing Medicine Production Clinical Trials 264

XTalks

MAY 28, 2024

Dr. Clay’s insights offer a view into the changing landscape of clinical trials, where digital endpoints and wearable sensors are emerging as drivers of change in drug development. This approach can speed up development and improve data quality, potentially leading to more effective and personalized therapies.

Clinical Development 111

Clinical Development Development Clinical Trials Clinical Trials 111

Pharmaceutical Technology

APRIL 26, 2024

In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers.

Medicine 130

Medicine Development Drugs Marketing 130

Pharmaceutical Technology

NOVEMBER 21, 2022

RVAC Medicines has signed a master research partnership agreement with the Agency for Science, Technology and Research (A*STAR) for analysing and developing solutions to build messenger ribonucleic acid (mRNA) manufacturing and analytics expertise in Singapore. Topic sponsors are not involved in the creation of editorial content.

Manufacturing 130

Manufacturing Medicine Vaccination Vaccine 130

Pharmaceutical Technology

JULY 1, 2022

Blueprint Medicines has entered strategic financing partnerships for up to $1.25bn with life sciences-focused investors Sixth Street and Royalty Pharma. The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects.

Medicine 147

Medicine Business Development Sales Life Science 147

Pharmaceutical Technology

APRIL 5, 2023

The European Medicines Agency (EMA) has announced plans to expedite scientific advice and support the preparation of regulatory packages under its PRIority Medicines (PRIME) scheme. PRIME is an EMA scheme to support the development of medicines for rare diseases and conditions with high unmet need.

Development 130

Development Drugs Medicine Production 130

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Pharmaceutical Technology

APRIL 5, 2023

Luye Pharma Group has signed a marketing and distribution agreement with Duopharma Biotech’s wholly-owned subsidiary, Duopharma Marketing, for a cholesterol management product in Malaysia. Both the companies are targeting a double-digit compound annual growth rate for the product in the local market over the next ten years.

Production 130

Production Marketing Doctors Doctor 130

Pharmaceutical Technology

JANUARY 5, 2023

Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases. The post Capsida Biotherapeutics and Prevail to develop CNS gene therapies appeared first on Pharmaceutical Technology.

Gene Therapy 237

Gene Therapy Gene Development Engineer 237

Pharmaceutical Technology

JUNE 19, 2023

Oral liquid medicine manufacturer Rosemont Pharmaceuticals has announced the acquisition of Lucis Pharma. UK-based Rosemont hopes that this latest acquisition will bolster its portfolio with a pipeline of innovative products and allow it to serve the UK and overseas markets. Free Report How is the Biopharmaceutical industry evolving?

Medicine 130

Medicine Marketing Manufacturing Production 130

Pharmaceutical Technology

FEBRUARY 9, 2023

The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies. ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients.

Development 241

Development RNA Gene Therapy Genetics 241

Pharmaceutical Technology

MAY 22, 2023

The European Medicines Agency (EMA) has accepted and verified Sobi’s marketing authorisation application for a new factor VIII (FVIII), efanesoctocog alfa, to treat haemophilia A patients of all ages. Haemophilia A is a rare genetic disorder in which blood-clotting ability is impaired because of the absence of FVIII.

Marketing 217

Marketing Genetics Trials Medicine 217

Pharmaceutical Technology

DECEMBER 9, 2022

Brazil is the largest country in Latin America, with a population of over 212 million, and consequently has the biggest pharmaceutical market in the region. Brazilian public spending on healthcare, drug pricing reforms and remote medicine. The generics market in Brazil.

Marketing 246

Marketing Sales Production Medicine 246

Pharmaceutical Technology

JULY 7, 2022

But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. Although a high number of cell and gene therapies are in early-stage development, a new wave of approvals could be on its way. Securing the supply chain. The industry is moving at an unprecedented speed.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

BioPharma Reporter

MARCH 26, 2024

Teva UK and Closed Loop Medicine have announced a strategic partnership to advance the development of personalized medicine.

Medicine 52

Medicine Development Regulation Marketing 52

Bio Pharma Dive

JULY 9, 2021

Zynteglo sales have been on hold since February, when a patient in a clinical trial of another, related Bluebird medicine developed leukemia.

Gene Therapy 263

Gene Therapy Gene Marketing Clinical Trials 263

Drug Discovery World

JULY 15, 2022

Pharmaceutical company Transpire Bio will work alongside drug delivery provider Recipharm to develop two inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).? . Transpire Bio announced a definitive agreement with Recipharm to develop its TRB-1 and TRB-2 inhaled medicines.

Medicine 52

Medicine Development Drug Delivery Production 52

Pharmaceutical Technology

MAY 26, 2023

The European Medicines Agency (EMA) has accepted two marketing authorisation applications (MAA) from Sandoz for the proposed biosimilar denosumab. The MAAs include all indications covered by the Xgeva (denosumab) and Prolia (denosumab) reference medicines to treat conditions such as osteoporosis in postmenopausal women.

Marketing 130

Marketing Packaging Packaging Medicine 130

Pharmaceutical Technology

APRIL 26, 2023

This investment will be used to further the development of the Singapore-based pharmaceutical company’s solid tumour-focused monoclonal antibodies. The funding and a prize-win from Amgen will support the company’s drug development plans as Singapore continues developing its pharmaceutical market.

Development 256

Development Drugs Marketing Protein 256

Pharmaceutical Technology

FEBRUARY 16, 2023

The University of Texas MD Anderson Cancer Center has entered a strategic collaboration with biotech company Xilis for advancing new technology and expediting new cancer therapy development. Under the deal, MD Anderson and Xilis aim to advance the development of drug and discovery projects using the MOS technology.

Development 242

Development Gene Therapy Gene Drugs 242

Bio Pharma Dive

MARCH 6, 2024

Incubated by RA Capital and backed by a wide array of investors, the startup is developing drugs that work differently than Vertex’s market-leading medicines.

Medicine 180

Medicine Marketing Development Drugs 180

Pharmaceutical Technology

AUGUST 30, 2022

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.

Development 130

Development Drugs Bioavailability Production 130

Roots Analysis

JANUARY 19, 2024

Introduction In a strategic move to accelerate the development and launch of genetic medicines, BridgeBio Pharma has successfully secured up to USD 1.25 Billion to Propel Genetic Medicine Development appeared first on Blog. billion from Blue Owl Capital and Canada Pension Plan Investment Board.

Genetics 40

Genetics Medicine Development Sales 40

Pharmaceutical Technology

FEBRUARY 15, 2023

JSR Life Sciences’ business unit Similis Bio is planning to collaborate with Novel351k for the development of three biosimilar programmes targeting cancer and autoimmune diseases. Under the terms of the initial deal, Similis Bio will handle the development of cell lines, analytics, process development, and cGMP production.

Development 147

Development Life Science Manufacturing Clinical Trials 147

Pharmaceutical Technology

MARCH 7, 2023

Abacus Medicine Pharma Services (AMPS) and AddMedica are proud to announce the signing of a partnership agreement for the marketing and distribution of Siklos® in Benelux. 100mg (3422086) Abacus Medicine Pharma Services is part of the Abacus Medicine Group, a fast-growing supplier of original prescription medicines.

Medicine 130

Medicine Marketing Production DNA 130

Pharmaceutical Technology

JULY 25, 2022

The European Commission (EC) has extended Bavarian Nordic ’s smallpox vaccine Imvanex (MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic) marketing authorisation to offer protection from monkeypox. A non-replicating smallpox vaccine, Imvanex was developed in partnership with the US Government.

Vaccination 130

Vaccination Vaccine Marketing Medicine 130

Pharmaceutical Technology

DECEMBER 9, 2022

The European Commission (EC) has granted marketing authorisation for Takeda ’s Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) to prevent dengue in people aged four years and above. The post EC grants marketing authorisation for Takeda’s dengue vaccine appeared first on Pharmaceutical Technology.

Vaccination 147

Vaccination Vaccine Marketing Trials 147

Pharmaceutical Technology

JANUARY 26, 2023

Such is the pace at which treatments are being developed that the medical landscape within the next decade could look radically different to how it does presently. With cell and gene therapy, not only does it offer the management of symptoms like other conventional medicines, but it also offers the potential of a cure.

Gene Therapy 130

Gene Therapy Gene Medicine Manufacturing 130

Pharmaceutical Technology

NOVEMBER 8, 2022

Fulgent Genetics has acquired clinical-stage therapeutics development firm Fulgent Pharma for a total deal price of nearly $100m. With the takeover, Fulgent Genetics intends to transform into a completely integrated precision medicine firm focusing on oncology from a genomic diagnostic business.

Genetics 130

Genetics Development Genome Genomics 130